7-Aug-2026
Ardelyx falls on lower projected Ibsrela sales, Q2 misses
Seeking Alpha News (Fri, 7-Aug 10:56 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Fri, 7-Aug 7:37 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 7-Aug 6:20 AM ET)
TipRanks (Thu, 6-Aug 9:50 PM ET)
Ardelyx Updates Outlook Amid Q2 Growth and Recalibration
TipRanks (Thu, 6-Aug 4:57 PM ET)
Ardelyx GAAP EPS of -$0.07 misses by $0.01, revenue of $120.8M misses by $0.84M
Seeking Alpha News (Thu, 6-Aug 4:43 PM ET)
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 6-Aug 10:00 AM ET)
Ardelyx’s Q2 2026 Earnings Announcement Sets the Stage for Key Pipeline Updates
Market Chameleon (Thu, 23-Jul 5:30 AM ET)
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
Globe Newswire (Thu, 23-Jul 8:01 AM ET)
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of August 7, 2026, ARDX stock price declined to $4.00 with 19,301,455 million shares trading.
ARDX has a beta of 1.13, meaning it tends to be more sensitive to market movements. ARDX has a correlation of 0.04 to the broad based SPY ETF.
ARDX has a market cap of $988.12 million. This is considered a Small Cap stock.
Last quarter Ardelyx reported $118 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$.03.
In the last 3 years, ARDX traded as high as $10.13 and as low as $3.16.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ARDX has underperformed the market in the last year with a price return of -22.2% while the SPY ETF gained +23.5%. ARDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.7% and -20.5%, respectively, while the SPY returned +6.0% and +4.6%, respectively.
ARDX support price is $4.75 and resistance is $4.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX shares will trade within this expected range on the day.